After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Recently, Yahoo Finance discussed the stock, revealing that Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
SRPT belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $134.61 and fluctuated between $143.00 as its day high and $134.06 as its day low. The current market capitalization of Sarepta Therapeutics Inc is $12.59B. A total of 2.76 million shares were traded on the day, compared to an average of 1.20M shares.
Insider Activity
Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, SRPT has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 25 BUYs and 19 SELLs from insiders. Insiders purchased 202,418 shares during that period but sold 28,026.
In the most recent transaction, Barry Richard bought 50,000 shares of SRPT for 78.81 per share on Nov 03. After the transaction, the Director now owns 140,000 company shares. In a previous transaction on Nov 03, INGRAM DOUGLAS S bought 25,225 shares at 79.36 per share. SRPT shares that President & CEO owns now total 390,307.
Among the insiders who bought shares, Chambers Michael Andrew acquired of 9,979 shares on Aug 14 at a per-share price of $109.47. This resulted in the Director holding 246,996 shares of SRPT after the transaction. In another insider transaction, Chambers Michael Andrew bought 23,686 shares at $108.05 per share on Aug 11. Company shares held by the Director now total 237,017.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for SRPT in the last 3 months, the mean price target is $157.23 with high estimates of $224.00 and low estimates of $103.00. In terms of 52-week highs and lows, SRPT has a high of $159.89 and a low of $55.25.
As of this writing, SRPT has an earnings estimate of $Sarepta Therapeutics, Inc. per share for the current quarter. EPS was calculated based on a consensus of CRPT estimates, with a high estimate of $Sprout Social, Inc per share and a lower estimate of $RSPT.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. SRPT’s latest balance sheet shows that the firm has $2.12B in Cash & Short Term Investments as of fiscal 2021. There were $1.15B in debt and $452.73M in liabilities at the time. Its Book Value Per Share was $8.17, while its Total Shareholder’s Equity was $928.01M.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for SRPT is Buy with a score of 4.52.
